Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects
These preclinical results demonstrate that conditional 4-1BB stimulation combined with complete PD-1 blockade enhances antitumor immunity through complementary mechanisms. The acasunlimab and pembrolizumab combination is being evaluated in Phase 2 (NCT05117242) and pivotal Phase 3 (NCT06635824) trials in patients with metastatic non-small cell lung cancer after checkpoint inhibitor therapy failure.
Authors
- Vanessa M Spires
- Bruna de Andrade Pereira
- Craig J. Thalhauser
- Brandon W. Higgs (ORCID: https://orcid.org/0000-0002-2951-0245)
- Angelica Sette (ORCID: https://orcid.org/0000-0002-3757-5583)
- Theo S. Plantinga (ORCID: https://orcid.org/0000-0003-4990-6084)
- Maria Jure‐Kunkel (ORCID: https://orcid.org/0000-0002-3751-1934)
- Saskia M. Burm (ORCID: https://orcid.org/0000-0002-5000-2026)
- Andrea Imle (ORCID: https://orcid.org/0000-0002-8740-1477)
- Kristina B Nürmberger
- Kristin Strumane
- Aras Toker (ORCID: https://orcid.org/0000-0001-6601-0939)
- Uğur Şahin (ORCID: https://orcid.org/0000-0003-0363-1564)
- Sina Fellermeier-Kopf
- Mark Fereshteh
- Tahamtan Ahmadi (ORCID: https://orcid.org/0009-0007-5031-3792)
- Alexander Muik (ORCID: https://orcid.org/0000-0003-4561-2273)
- Nora Pencheva (ORCID: https://orcid.org/0009-0006-4689-1218)
- Christina Yu
- Patricia Garrido Castro (ORCID: https://orcid.org/0000-0002-4677-9465)
- Michela Capello (ORCID: https://orcid.org/0000-0001-5810-6375)
- Özlem Türeci
- C. Dalla Costa (ORCID: https://orcid.org/0009-0006-3192-9156)
- Jordan M. Blum
Institutions
- Genmab (United States) (US)
- Genmab (Netherlands) (NL)
- BioNTech (Germany) (DE)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-011377
- Citations
- 9
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 12.24